ESR1 and breast carcinoma: In regard to miR-1290, recent reports have revealed that its expression and its potential targets were associated with characteristics of estrogen receptor (ER)α-positive breast cancers while its elevated serum levels were found to be associated with patients with low-stage pancreatic cancers [53], [54].